Executive Summary
Key takeaways:
- The FDA has entered its AI enforcement era: AI deployed in regulated environments now faces a far more assertive enforcement posture.
- If AI informs labeling, performance claims, dosing, safety, or decision-making, the entire solution must meet device-level quality, validation, and lifecycle controls.
- The January 2025 FDA draft guidance sets expectations for context-specific validation, model transparency, data integrity, bias mitigation, and continuous performance monitoring.
- Use the 10-point GxP readiness checklist to inventory AI systems, classify them by risk, qualify vendors, and prepare answers before FDA auditors ask.
Adoption of Artificial Intelligence technologies is accelerating across therapeutic product development, clinical operations, manufacturing, and quality systems—but the FDA is now signaling a far more assertive enforcement posture for AI deployed in regulated environments.
A recent AI-related warning letter revealed the agency’s expectations:
If AI informs labeling, performance claims, dosing, safety, or decision-making—then the entire solution must meet device-level quality, validation, and lifecycle controls.
This article explains:
- What changed in the FDA’s approach to AI
- Why both Quality/Regulatory and IT/Data leaders must act
- What the January 2025 FDA draft guidance really means
- How to prepare your AI systems, vendors, and teams for compliance
- How USDM can help operationalize AI safely and compliantly
The FDA Has Entered Its AI Enforcement Era
For years, AI innovation outpaced regulation. Many companies treated AI models—or vendor-supplied AI features—as “non-product” tools outside traditional validation expectations.
That era is over.
A defining moment: FDA’s warning letter to Exer Labs
The FDA issued a warning letter citing the company’s AI motion-analysis system used for musculoskeletal assessments. The agency classified the system as a medical device and cited deficiencies across:
- Design controls
- AI/ML model validation
- Data integrity
- Risk management
- CAPA, audit trails, and documentation
The takeaway was unmistakable:
When AI influences regulated decisions, the AI solution must meet full device-level requirements.
The FDA’s warning letter to Exer Labs classified an AI motion-analysis system as a medical device and cited deficiencies across design controls, AI/ML model validation, data integrity, risk management, and CAPA, audit trails, and documentation—a clear signal that AI influencing regulated decisions must meet full device-level requirements.
This is a direct signal to pharma, biotech, digital health, MedTech, and hybrid data-driven organizations. Below, I summarize what’s happening, why it matters, and how USDM is uniquely positioned to help companies get ahead of regulatory expectations.
The FDA’s New Enforcement Posture: AI Is a Regulated Technology
In April 2025, the FDA issued a warning letter to Exer Labs, citing misclassification of an AI-enabled diagnostic product, absence of required 510(k) clearance, and significant gaps in their Quality System (QS). Specific failures included:
- Missing design controls
- No CAPA procedures
- Insufficient audit trails
- Unqualified suppliers
- Training deficiencies
At its core, there were gaps in the quality management system The takeaway was unmistakable; when AI influences regulated decisions, the AI solution must meet full device-level requirements. This case demonstrates how quickly an AI application can cross the line into regulated territory and trigger full device-level expectations. Exer Labs attempted to bring to market a medical device with enhanced/diagnostic claims (AI-based screening, diagnosing, treating) without the regulatory foundation for that intended use (no pre-market clearance/approval) and without mature quality-systems practices required for regulated medical-device manufacture. In essence: the company scaled a novel use-case without establishing both regulatory compliance for the device’s intended claims and a robust quality-management system to support manufacturing and post-market controls.
Why the FDA’s Shift Matters Across the Organization
The implications extend beyond Compliance and Quality.
AI touches entire business processes—meaning compliance gaps can surface anywhere data flows.
For Quality & Regulatory (QA/RA):
- AI is now subject to design control rigor, not just CSA “scriptless” testing.
- Traceability, provenance, and explainability become compliance requirements.
- You must be able to show how AI outputs are verified, monitored, and controlled.
For IT, Digital, Data, and AI teams:
- Vendor-supplied AI features (e.g., “smart” modules) now have regulatory implications.
- Model lifecycle management, drift monitoring, and bias detection need discipline.
- Data pipelines feeding AI must meet GxP integrity and transparency standards.
For Executives:
- AI risk is now business risk.
- The FDA expects governance systems, not experiments.
- AI investments need compliance readiness baked in from the start.
Inside the FDA’s January 2025 Draft Guidance on AI
The 2025 draft guidance marks the FDA’s strongest effort to date to define expectations for AI used in:
- Clinical trial analysis
- Therapeutic product development
- Digital health tools
- Manufacturing
- Quality systems
- Post-market safety monitoring
Key expectations include:
1. Context-Specific Validation
Validation must reflect intended use, training data, and real-world operating conditions.
2. Model Transparency & Explainability
Organizations must document:
- What data trained the model
- How features were selected
- The model’s decision logic (to the extent possible)
3. Data Integrity & Governance
AI must comply with ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available), including:
- Access control
- Immutable audit trails
- Versioning
- Data lineage
How regulated AI should move from idea to inspection-ready operation
Define the use
- Intended use: claims, users, decision context
- Risk class: patient safety, GxP impact, product quality
- System boundary: model, data, workflow, vendor features
Control the evidence
- Validation: acceptance criteria and performance testing
- Data integrity: lineage, access, ALCOA+ records
- Transparency: explainability, bias review, audit trail
Operate with oversight
- Monitoring: drift, exceptions, complaints, retraining triggers
- Change control: PCCP fit, validation impact, approval path
- Inspection answer: who approved what, why, and with what evidence
Connect each use case to regulated impact before selecting controls.
Keep source, training, validation, and monitoring evidence traceable.
Define human oversight for safety, quality, bias, and drift signals.
Route model, workflow, and vendor updates through risk-based change control.
Preserve the rationale, approval path, and evidence behind AI decisions.
4. Bias Mitigation Requirements
Models must demonstrate:
- Fairness assessments
- Bias detection
- Corrective measures
- Ongoing monitoring
5. Continuous Performance Monitoring
AI is never validated once. The FDA expects ongoing lifecycle evaluation, including:
- Drift monitoring
- Retraining controls
- Change management
This bridges FDA expectations with leading frameworks like GMLP, ICH E6(R3), ICH Q9, and NIST AI RMF.
What Life-Science Companies Must Do Now
Here’s what your organization should prioritize within the next 6–12 months.
1. Establish AI Governance & Accountability
Move from experimentation to an operating model:
- AI governance board
- Responsible AI principles
- Risk classification
- Vendor oversight
- Clear ownership across QA, IT, and business teams
2. Classify All AI Systems According to Risk
Build (or adapt) your AI inventory to classify systems as:
- High-risk (decision support, patient safety, QC inspection, deviation management)
- Medium-risk (forecasting, operations optimization)
- Low-risk (productivity, reporting)
Tie controls to risk—not hype.
3. Qualify Vendors and Third-Party AI Features
Most AI solutions your teams touch will come from vendors.
The FDA expects:
- Vendor audits
- Security and bias controls
- Architecture transparency
- Validation and model documentation
- Clear change-control procedures
This is where organizations are currently least prepared.
4. Strengthen Validation, Data Integrity, and Traceability Controls
Validation of AI looks more like validation of analytics, modeling, and decision engines—not simple feature/function testing.
Key elements include:
- Model evaluation protocol (accuracy, sensitivity, drift thresholds)
- Data lineage and traceability
- Performance monitoring plans
- Training/validation/test data documentation
- Explainability and bias testing
5. Prepare for FDA Questions Before They Come
When auditors see AI outputs influencing regulated decisions, they will ask:
- “How do you know the model is performing correctly today?”
- “How do you detect drift?”
- “What controls prevent unintended behavior?”
- “Who approved the last retraining cycle?”
- “Can you trace this output back to an auditable input?”
Your teams need answers ready—now.
AI in GxP: 10-Point Readiness Checklist
- Inventory all AI systems and classify by risk.
- Identify AI features embedded in vendor tools.
- Establish cross-functional AI governance roles.
- Document intended use, data sources, and training data.
- Create model validation & monitoring procedures.
- Implement bias detection and mitigation controls.
- Ensure traceability, versioning, and immutable audit trails.
- Map data lineage from raw input to model output.
- Qualify vendors and require transparency documentation.
- Create a change-control and post-release monitoring plan.
FDA PCCP Guidance and AI Lifecycle Management
The FDA's final guidance on Predetermined Change Control Plans for Artificial Intelligence-Enabled Device Software Functions makes one point clear for AI lifecycle management: planned model or software changes need to be bounded, justified, verified, and controlled before they are implemented.
A predetermined change control plan, or PCCP, lets an AI-enabled device manufacturer describe certain planned modifications, the protocol for implementing and controlling those modifications, and the impact assessment for those changes. The FDA reviews the PCCP as part of a marketing submission so specific authorized modifications can be managed without a new marketing submission for each change.
What a strong FDA PCCP operating model needs
- Description of modifications: the specific AI-enabled device software changes the manufacturer intends to make.
- Modification protocol: the verification, validation, acceptance criteria, implementation controls, and rollback or stop mechanisms for planned changes.
- Impact assessment: documented analysis showing that the planned changes preserve safety, effectiveness, intended use, and risk controls.
- Lifecycle monitoring: ongoing performance monitoring, drift detection, issue escalation, and evidence review after deployment.
For life sciences companies, the practical lesson is broader than medical device submissions. FDA PCCP guidance reinforces the same governance pattern that regulated AI programs need everywhere: define intended use, control change, monitor performance, preserve evidence, and make lifecycle decisions traceable.
Five PCCP principles life sciences teams should operationalize
The FDA, Health Canada, and MHRA also published five guiding principles for PCCPs in machine learning-enabled medical devices. Those principles are useful beyond a single submission package because they describe what disciplined AI lifecycle governance should look like.
- Focused and bounded: planned changes should stay within the intended use or intended purpose of the original device or workflow.
- Risk-based: change controls should reflect patient, product, quality, and business impact rather than treating every change the same.
- Evidence-based: performance claims, validation decisions, and release readiness should be supported by scientifically and operationally appropriate evidence.
- Transparent: users and stakeholders should understand relevant device behavior, change boundaries, monitoring, and response plans.
- Total product lifecycle perspective: AI lifecycle management should span design, implementation, deployment, monitoring, maintenance, and retirement.
That is why AI lifecycle compliance cannot live only in model-development teams. Quality, Regulatory, IT, Cybersecurity, Data, and business process owners all need a shared operating model for AI-enabled change.
How USDM Helps Organizations Operationalize AI Safely
USDM brings 25+ years of life-sciences compliance expertise combined with deep AI technical understanding to help you move from experimentation to enterprise-grade AI.
Our support includes:
- AI Assessment & Readiness Review
- AI Assurance Framework
- AI Vendor Qualification & Third-Party Risk Assessment
- CSA/CSV for AI-enabled systems
- Model lifecycle validation & monitoring controls
- Data integrity, lineage, and traceability architecture
- AI governance framework design
- Documentation packages for audits & inspections
- Data Architecture & Strategy
- Data Ingestion and Pipelines
AI does not relax compliance requirements—it amplifies the need for transparency, governance, and control.
What Happens Next: The AI Compliance Landscape Will Keep Accelerating
Expect further FDA guidance on:
- Adaptive AI (continually learning models)
- SaMD and clinical decision support
- AI in manufacturing analytics and real-time release
- AI-driven quality management systems
- AI transparency standards
Preparing now puts your organization ahead—not just in compliance, but in AI-enabled innovation.
Frequently Asked Questions
FAQ: FDA PCCP Guidance and AI Lifecycle Compliance
What does it mean that the FDA has entered its “AI enforcement era”?
For years AI innovation outpaced regulation, and many companies treated AI models or vendor-supplied AI features as “non-product” tools outside traditional validation expectations. That era is over. The FDA is now signaling a far more assertive enforcement posture for AI deployed in regulated environments, expecting governance systems rather than experiments.
What did the FDA’s warning letter to Exer Labs establish?
In April 2025 the FDA cited misclassification of an AI-enabled diagnostic product, absence of required 510(k) clearance, and significant gaps in the Quality System—including missing design controls, no CAPA procedures, insufficient audit trails, unqualified suppliers, and training deficiencies. The case shows how quickly an AI application can cross into regulated territory and trigger full device-level expectations.
What does FDA PCCP guidance expect organizations to document?
FDA PCCP guidance expects organizations to define the planned AI-enabled device software modifications, the protocol for implementing and controlling those changes, and the impact assessment showing continued safety and effectiveness. In practice, that means intended use, validation evidence, performance monitoring, drift controls, retraining governance, and change-management records need to be ready before changes move into use.
How should we classify our AI systems?
Build or adapt an AI inventory and classify systems by risk: high-risk (decision support, patient safety, QC inspection, deviation management), medium-risk (forecasting, operations optimization), and low-risk (productivity, reporting). Tie controls to risk, not hype.
How quickly should life sciences companies act?
Organizations should prioritize within the next 6–12 months—establishing AI governance and accountability, classifying AI systems by risk, qualifying vendors and third-party AI features, strengthening validation and traceability controls, and preparing answers to FDA questions before they come.
How does PCCP guidance change AI lifecycle management?
PCCP guidance pushes AI lifecycle management toward planned, bounded, evidence-based change. Teams need to know which modifications are authorized, how they will be verified and validated, how performance will be monitored, and how failed or out-of-bounds changes will be stopped, reverted, or escalated.
Act Now
If your organization is deploying or evaluating AI, now is the time to ensure you’re prepared for FDA expectations. Contact USDM to schedule your AI Readiness Assessment and build a clear, compliant path to safe, scalable AI adoption.
Additional Resources
Read our white paper on Anticipating Regulatory Compliance for Artificial Intelligence in Life Sciences or check out these AI case studies to learn more.